MACRO Consulting Group raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 11,508 shares of the company’s stock after purchasing an additional 466 shares during the period. MACRO Consulting Group’s holdings in Johnson & Johnson were worth $1,608,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in Johnson & Johnson by 1.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,399,820 shares of the company’s stock worth $1,727,047,000 after buying an additional 209,429 shares during the last quarter. Fisher Asset Management LLC grew its stake in Johnson & Johnson by 2.6% during the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after purchasing an additional 301,124 shares during the last quarter. Clearbridge Investments LLC grew its stake in Johnson & Johnson by 0.5% during the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after purchasing an additional 48,582 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Johnson & Johnson by 14.2% in the first quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after purchasing an additional 1,079,751 shares during the period. Finally, Prudential Financial Inc. increased its holdings in shares of Johnson & Johnson by 8.1% in the second quarter. Prudential Financial Inc. now owns 5,171,858 shares of the company’s stock valued at $720,336,000 after purchasing an additional 386,047 shares during the period. Institutional investors and hedge funds own 72.12% of the company’s stock.
JNJ stock traded up $1.33 during midday trading on Wednesday, hitting $130.88. 2,304,302 shares of the company’s stock were exchanged, compared to its average volume of 7,544,466. The stock has a market capitalization of $335.04 billion, a PE ratio of 16.00, a P/E/G ratio of 2.15 and a beta of 0.68. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The business has a 50-day simple moving average of $130.07 and a two-hundred day simple moving average of $135.99.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter last year, the firm posted $2.10 earnings per share. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $0.95 dividend. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.90%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.
Several brokerages recently weighed in on JNJ. Credit Suisse Group set a $156.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Finally, Bank of America restated a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $150.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.